Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma.

Area of Science:

• Mitochondrial apoptosis regulation
• Cancer therapy resistance
• Diffuse mesothelioma biology

Background:

• Diffuse mesothelioma (DM) is an aggressive cancer with limited treatment options and high resistance.
• Anti-apoptotic proteins MCL-1 and BCL-xL contribute to therapeutic resistance in DM.
• Understanding BH3 profiles is key to overcoming treatment resistance.

Purpose of the Study:

• To assess BH3 profile consistency across patient samples and models.
• To investigate the efficacy of co-targeting MCL-1 and BCL-xL.
• To evaluate the potential of targeting MCL-1 as a safe therapeutic strategy for DM.

Main Methods:

• BH3 profiling to compare patient tumors, patient-derived cells (PDCs), and patient-derived xenografts (PDXs).
• In vitro and in vivo experiments co-targeting BCL-xL and MCL-1.
• Assessment of apoptosis, cell viability, and toxicity in PDX models.

Main Results:

• BH3 profiles were consistent between intra-patient samples, PDCs, and PDXs.
• Co-targeting BCL-xL and MCL-1 induced synergistic lethality in vivo, indicating a lack of safety.
• Targeting MCL-1 alone decreased the mitochondrial threshold for apoptosis and enhanced chemosensitivity without toxicity.

Conclusions:

• MCL-1 inhibition, not combined BCL-xL and MCL-1 targeting, is a potentially safe and effective strategy for DM.
• Targeting MCL-1 enhances chemotherapy efficacy by sensitizing cells to apoptosis.
• This research provides a foundation for developing safer Bcl-2 targeted therapies for DM.